All In Biotech

Free tool

FAERS Monitor: Xenleta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211673 or its brand name (Xenleta, Lefamulin Acetate). Reports on generic versions are filed under their own applications.

Reports

55

Serious

35

64% of reports

Hospitalization

5

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use27
  • drug hypersensitivity26
  • product use in unapproved indication26
  • toxic epidermal necrolysis25
  • diarrhoea7
  • vomiting7
  • hypotension6
  • pain5
  • dyspnoea4
  • hypersensitivity4
  • condition aggravated3
  • death3
  • drug ineffective3
  • headache3
  • nausea3

Reports by year received

View as table
YearReports
20073
20111
202018
202117
20228
20233
20241
20251
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,104 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
toxic epidermal necrolysisSignal25630.6471.915,077
drug hypersensitivitySignal2651.438.91,246
product use in unapproved indicationSignal2640.130.3964
off label useSignal2711.89.0267
hypotensionSignal611.45.448
hypersensitivitySignal48.23.219
vomitingSignal75.72.823
diarrhoeaSignal74.12.114
condition aggravated33.81.34
painSignal53.11.35
dyspnoea42.71.13
headache31.80.60
nausea31.40.50
death31.30.40
drug ineffective30.90.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.